High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma

Cancer

Volumn 79, Issue 5, 1997, Pages 878-883

  Cho, Jae Yong ^a   Chung, Hyun Cheol ^a   Noh, Sung Hoon ^b   Roh, Jae Kyung ^a   Min, Jin Sik ^b   Kim, Byung Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

gastric carcinoma; invasion and metastasis; plasminogen activator inhibitor 1 (PAI 1); urokinase type plasminogen activator (uPA)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TUMOR MARKER; UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA;

ADULT; AGED; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GASTRIC MUCOSA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842296358     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970301)79:5<878::AID-CNCR2>3.0.CO;2-8     Document Type: Article

References (27)

1. Ministry of Health and Social Affairs Republic of Korea. Report of central cancer registry programme in Korea 1 July 1989-30 June 1990. 1990;3:1.
2. Kim JP. Gastric cancer: recent advances in therapy. Med Prog Technol 1994; 16:5-7.
3. Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46:1-7.
4. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49:636-49.
5. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989; 49:2533-53.
6. Wilhelm O, Hafter R, Henschen A, Schmitt M, Graeff H. Role of plasmin in the degradation of the stroma derived fibrin in human ovarian carcinoma. Blood 1990; 75:1673-8.
7. Harvey SR, Lawrence DD, Madeja JM, Abbey SJ, Markus G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin Exp Metastasis 1988; 6:431-50.
8. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
9. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986;261:15819-22.
10. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, et al. The receptor-binding sequence of urokinase. J Biol Chem 1987;262:4437-40.
11. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9.
12. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991;51:274-81.
13. Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognize the NH2 - terminal domain of the urokinase receptor. FEBS Lett 1991;288:233-6.
14. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992;52:3610-4.
15. Skriver L, Larson LI, Kielberg V, Nielson LS, Andresen PB, Kristensen P, et al. Immunohistochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984;99:752-7.
16. Burtin P, Chavanel G, Andre J. The plasmin system in human colonic tumors: an immunofluorescence study. Int J Cancer 1985;35:307-14.
17. Cajot JF, Kruithof EKO, Schleuning WD, Sordat B, Bachman F. Plasminogen activators, plasminmogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986;38:719-27.
18. Hansen JG, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, et al. High levels of urokinase type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor prognosis. Cancer Res 1993;53:2513-21.
19. Bouchet C, Spyratos F, Martin PM, Hacene K, Oglobine GJ. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
20. Reilly D, Christensen L, Duch M, Nolan N, Duffy M, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992;50:208-14.
21. Janike F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
22. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
23. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1981;11:127-39.
24. Thorpe SM. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 1987;9:175-89.
25. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loers U, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase type plasminogen activator system. J Clin Oncol 1995;13:2084-93.
26. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigen CA19-9 and carcinoembronic antigen. Cancer Res 1993;53:1788-93.
27. Soff GA, Sendrowicz J, Takano S, Verrusio E, Weiss I, Brem S, et al. PAI-1 expression human prostate carcinoma cells inhibits primary tumor growth, tumor associated angiogenesis and metastasis in an athymic mouse carcinoma model. Proc Am Assoc Cancer Res 1995;36:101.